Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT

Piera Angelillo; Ana Alarcon Tomas; Edoardo Campodonico; Urban Novak; Ludovic Gabellier; Igor Wolfgang Blau; Mi Kwon; Ron Ram; Edouard Forcade; Caroline Besley; Vladan Vucinic; Nicolaus Kröger; Lucía López Corral; Jan Vydra; Silvia Ferrari; Bastian von Tresckow; Marie Therese Rubio; Rafael Hernani; Simona Sica; Friedrich Stölzel; Montserrat Rovira; Eva Wagner-Drouet; Jose Antonio Pérez-Simón; Cristina Castilla-Llorente; Andres J M Ferreri; Jorinde D Hoogenboom; Isabel Sanchez Ortega; Florent Malard; Jürgen Kuball; Annalisa Ruggeri

doi:10.1038/s41409-024-02451-8

Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT

Bone Marrow Transplant. 2024 Oct 25. doi: 10.1038/s41409-024-02451-8. Online ahead of print.

Authors

Piera Angelillo^#¹, Ana Alarcon Tomas^#², Edoardo Campodonico^#¹, Urban Novak³, Ludovic Gabellier⁴, Igor Wolfgang Blau⁵, Mi Kwon^{6

7}, Ron Ram⁸, Edouard Forcade⁹, Caroline Besley¹⁰, Vladan Vucinic¹¹, Nicolaus Kröger¹², Lucía López Corral¹³, Jan Vydra¹⁴, Silvia Ferrari¹⁵, Bastian von Tresckow¹⁶, Marie Therese Rubio¹⁷, Rafael Hernani¹⁸, Simona Sica¹⁹, Friedrich Stölzel²⁰, Montserrat Rovira²¹, Eva Wagner-Drouet²², Jose Antonio Pérez-Simón²³, Cristina Castilla-Llorente²⁴, Andres J M Ferreri¹, Jorinde D Hoogenboom²⁵, Isabel Sanchez Ortega²⁶, Florent Malard²⁷, Jürgen Kuball²⁸, Annalisa Ruggeri²⁹

Affiliations

¹ San Raffaele Scientific Institute, Milan, Italy.
² Clinica Puerta de Hierro, Madrid, Spain.
³ Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
⁴ University Hospital of Montpellier, Montpellier, France.
⁵ Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany.
⁶ Department of Hematology, Hospital General Unversitario, Madrid, Spain.
⁷ Universidad Complutense de Madrid, Madrid, Spain.
⁸ Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
⁹ CHU Bordeaux, Hopital Haut-Leveque, Pessac, France.
¹⁰ University Hospitals Bristol and Weston NHSFT, Bristol, United Kingdom.
¹¹ Medical Clinic and Policinic 1, Leipzig, Germany.
¹² University Hospital Eppendorf, Hamburg, Germany.
¹³ Hospital Universitario de Salamanca (Spain), IBSAL, CIBERONC, Salamanca, Spain.
¹⁴ Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
¹⁵ ASST Papa Giovanni XXIII, Bergamo, Italy.
¹⁶ Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.
¹⁷ CHRU NANCY, Nancy, France.
¹⁸ Hospital Clínico de Valencia, Valencia, Spain.
¹⁹ Universita Cattolica S. Cuore, Rome, Italy.
²⁰ University Hospital Schleswig-Holstein, Division of Stem Cell Transplantation and Cellular Immunotherapies, Kiel, Germany.
²¹ Hospital Clinic, Barcelona, Spain.
²² University Medical Center Mainz, Mainz, Germany.
²³ Department of Hematology, University Hospital Virgen Del Rocio, Instituto de Biomedicina de Sevilla (IBIS), CSIC, Universidad de Sevilla, Sevilla, Spain.
²⁴ Gustave Roussy Cancer Campus, Villejuif, France.
²⁵ EBMT Leiden Study Unit, Leiden, The Netherlands.
²⁶ EBMT Executive Office, Barcelona, Spain.
²⁷ Sorbonne Université, Hôpital Saint-Antoine, AP-HP, Service d'Hématologie Clinique et Thérapie Cellulaire, Paris, France.
²⁸ University Medical Center Utrecht, Utrecht, The Netherlands.
²⁹ San Raffaele Scientific Institute, Milan, Italy. [email protected].

^# Contributed equally.

PMID: 39455896
DOI: 10.1038/s41409-024-02451-8

No abstract available

Publication types

Letter